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http://dxObjective: There are currently no targeted therapies against lung tumors with oncogenic K-ras mutations that
are found in 25% to -40% of lung cancers and are characterized by their resistance to epidermal growth factor
receptor inhibitors. The isozyme group IIa secretory phospholipase A2 (sPLA2IIa) is a potential biomarker and
regulator of lung cancer cell invasion; however, the relationship between K-ras mutations and sPLA2IIa has yet
to be investigated. We hypothesize that sPLA2IIa modulates lung cancer cell growth in K-ras mutant cells and
that sPLA2IIa expression in human lung tumors is increased in K-ras mutant tumors.
Methods: Baseline sPLA2IIa expression in K-ras mutant lung cancer cell lines (A549, SW1573, H358, H2009)
was assessed. Cells were treated with a specific sPLA2IIa inhibitor and evaluated for apoptosis and cell viability.
Nuclear factor kappa-b (NF-kB) and extracellular signal-regulated kinase 1/2 activity were detected by Western
blot. Human tumor samples were evaluated for sPLA2IIa mRNA expression by quantitative reverse-
transcription polymerase chain reaction.
Results: Cytotoxicity of sPLA2IIa inhibition correlates with sPLA2IIa expression. Apoptosis in response to
sPLA2 inhibition parallels attenuation in NF-kB activity. In addition, sPLA2IIa expression in human tumors cor-
relates with squamous cell pathology and increasing stage of K-ras mutant lung tumors.
Conclusions: Baseline sPLA2IIa expression predicts response to sPLA2IIa inhibition in some K-ras mutant lung
cancer cells. This finding is independent of p53 mutation status. Furthermore, squamous tumors and advanced-
stage K-ras mutant tumors express more sPLA2IIa. These data support a role for sPLA2IIa as a potential global
therapeutic target in the treatment of lung cancer. (J Thorac Cardiovasc Surg 2012;144:1479-85)E
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SLung cancer remains the most lethal cancer in the world.
Gain-of-function mutations in K-ras are found in 25% to
40% of lung cancers and are thought to be significant drivers
of oncologic virulence. There are currently no targeted ther-
apies that effectively treat K-ras mutant lung tumors. In fact,
these mutations are characterized by their resistance to
epidermal growth factor receptor (EGFR) inhibitors.1,2
Phospholipase A2 (PLA2) enzymes release arachidonic
acid from cell membranes, initiating downstream produc-
tion of tumor-promoting eicosanoids. Group IIa secretory
phospholipase A2 (sPLA2IIa), a subgroup of PLA2s, has re-
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The Journal of Thoracic and CarIn a cohort of patients with solitary pulmonary nodules, pa-
tients with lung cancer had higher plasma levels of
sPLA2IIa than patients with a benign nodule. In addition,
histologic analysis demonstrates overexpression of
sPLA2IIa in lung tumors compared with normal lung tis-
sue.3 From a functional perspective, sPLA2IIa has been
shown to regulate lung cancer cell growth and invasion.
RNA interference of sPLA2IIa decreases tumor growth
and nuclear factor kappa-b (NF-kB) activity in a xenograft
model of lung cancer.4 In addition, sPLA2IIa inhibition
decreases intercellular adhesion molecule-1–associated in-
vasion in vitro.5
Although cytosolic PLA2 activity is increased in K-ras
mutant lung tumors,6-8 the relationship between sPLA2IIa
and K-ras mutant lung cancer has not previously been
explored. The aim of this study is to examine the
potential of targeted sPLA2IIa inhibition in K-ras mutant
lung cancer. Our purpose was twofold: (1) to investigate
the role of sPLA2IIa in the growth of K-ras mutant lung
cancer cells and (2) to examine sPLA2IIa expression in
human tumor specimens and correlate the results with
K-ras mutation status. We hypothesized that sPLA2IIa
modulates lung cancer cell growth in K-ras mutant cells
and that tumor expression of sPLA2IIa would correlate
with K-ras status and cancer stage.diovascular Surgery c Volume 144, Number 6 1479
Abbreviations and Acronyms
EGFR ¼ epidermal growth factor receptor
ERK ¼ extracellular signal-regulated kinase
FBS ¼ fetal bovine serum
GAPDH ¼ glyceraldehyde 3-phosphate
dehydrogenase
mRNA ¼ messenger RNA
MTT ¼ 3-(4,5-dimethylthiazol-2-yl)-2,
5-diphenyltetrazolium bromide
NF-kB ¼ nuclear factor kappa-b
PLA2 ¼ phospholipase A2
RT-PCR ¼ reverse-transcription polymerase chain
reaction
sPLA2IIa ¼ group IIa secretory phospholipase A2
TNF-a ¼ tumor necrosis factor-alpha
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Cells and Reagents
All cell lines tested were K-ras mutant derived from non–small cell lung
cancers (Table 1). A549 cells were a gift from Dr Anirban Banerjee (Au-
rora, Colo). H358 cells were a gift from Dr Kim O’Neill (Provo, Utah).
SW1573 and H2009 were a gift from Dr Mary Reyland (Aurora, Colo).
Cells were maintained in a humidified atmosphere with 5% carbon dioxide
using Ham’s F-12 (A549) or RPMI media (all other cell lines) with 10%
fetal bovine serum (FBS). Tumor necrosis factor-alpha (TNF-a) (Sigma-
Aldrich, St Louis, Mo) was used at a concentration of 20 ng/mL to mimic
the inflammatory milieu of the tumor microenvironment. The sPLA2IIa in-
hibitor S3319 (Sigma Aldrich) was dissolved in dimethyl sulfoxide. Di-
methyl sulfoxide served as a vehicle control for all experiments with
a maximum experimental concentration of 0.08%. Rabbit anti-human
antibodies for phosphorylated and total NF-kB p65, extracellular signal-
regulated kinase (ERK) 1/2, and glyceraldehyde 3-phosphate dehydroge-
nase (GAPDH) were obtained from Cell Signaling Technology, Inc
(Beverly, Mass). For Western blot, the rabbit anti-human–specific
sPLA2IIa antibody was from Abcam (Cambridge, Mass). For immunoflu-
orescence, the rabbit anti-human sPLA2IIa antibody was obtained from
BioVendor, LLC (Candler, NC).
Immunofluorescence Microscopy
We cultured 5000 cells per chamber on Lab-Tek II 8-well glass chamber
slides (Thermo Scientific, Rochester, NY) in full media for 24 hours and
then serum-starved them (0.5% FBS) for 24 hours. Cells were pretreated
with incrementally increasing concentrations of the sPLA2 inhibitor in
serum-starved media for 1 hour, then stimulated with 20 ng/mL TNF-a
for 8 hours. Control cells were incubated with dimethyl sulfoxide in
serum-starved media and stimulated with TNF-a for 8 hours. Immunoflu-
orescence microscopy was performed to evaluate sPLA2IIa expression in
A549 cells as previously described.9
Apoptosis Assay
We cultured 13 106 cells per well in 12-well plates in full media for 24
hours and then serum-starved them (0.5% FBS) for 24 hours before treat-
ment. Cells were treated with sPLA2IIa inhibitor (20 or 40 mmol/L) or ve-
hicle control in serum-starved media for 8 hours. A time-response
experiment using 4- and 8-hour time points was used to determine the
8-hour time point chosen for this experiment (data not shown). Apoptosis
was assessed by flow cytometric detection of annexin V and propidium
iodide (BD Biosciences, San Jose, Calif).1480 The Journal of Thoracic and Cardiovascular SurCell Viability Assay
We cultured 53 103 cells per well in 96-well plates in full media for 24
hours and then serum-starved them (0.5% FBS) for 24 hours before treat-
ment. Cells were exposed to sPLA2IIa inhibitor (10-40 mmol/L) or vehicle
control in serum-starved media for 24 hours. A time-response experiment
using 12-, 24-, and 48-hour time points was used to determine the 24-hour
time point chosen for this experiment (data not shown). Cell viability was
measured with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide (MTT) assay according to manufacturer instructions (Roche Applied
Science, Indianapolis, Ind).
Western Blot
Cells were plated on 6-well plates at a density of 3 3 106 in full media
for 24 hours, then serum-starved (0.5% FBS) for 24 hours, and then treated.
Time trials with TNF-a were performed to determine the time of maximal
initial increase in phosphorylation of NF-kB and ERK 1/2 in all cell lines.
Cells were pretreated with sPLA2IIa inhibitor (10-40 mmol/L) for 1 hour,
stimulated with TNF-a, then lysed with Laemmli buffer under reducing
conditions. In separate experiments, untreated cells were lysed and ana-
lyzed for baseline sPLA2IIa expression. Proteins were separated using so-
dium dodecyl sulfate–polyacrylamide gel electrophoresis techniques and
transferred to a nitrocellulose membrane. Membranes were blocked in
5% nonfat milk in phosphate-buffered saline–Tween. Primary antibodies
were dissolved in 5% bovine serum albumin in phosphate-buffered sa-
line–Tween. Secondary antibodies were prepared in 5% nonfat milk in
phosphate-buffered saline–Tween. The protein of interest was developed
using Pierce ECL Chemiluminescent (Thermo Fisher Scientific, Inc, Rock-
ford, Ill). Densitometric analysis was performed using ImageJ Software
(National Institutes of Health, Bethesda, Md).
Quantitative Reverse-Transcription Polymerase
Chain Reaction (RT-PCR)
Cells were plated on 12-well plates at a density of 13 106 in full media
for 24 hours and serum-starved (0.5% FBS) for 24 hours before lysis and
RNA isolation. RNAwas prepared using the Qiagen RNeasy Plus Mini Kit
according to the manufacturer’s protocol (Germantown,Md). Complemen-
tary DNA was synthesized using Bio-Rad iScript (Hercules, Calif). RT-
PCR was performed using Applied Biosystems Sybr Green Master Mix
(Carlsbad, Calif). The primer sequences used are as follows: sPLA2IIa (for-
ward): CCC-TCC-TAC-TGT-TGG-CAG-TGA-T; sPLA2IIa (reverse):
CCT-GTC-GTC-AAC-TTG-ATC-ATT-CTG; GAPDH (forward): CCT-
GCA-CCA-CCA-ACT-GCT-TAG; GAPDH (reverse): TGA-GTC-CTT-
CCA-CGA-TAC-CAA. Denaturation (95C, 15 seconds), annealing
(52C, 30 seconds), and elongation (72C, 30 seconds) steps were repeated
for 40 cycles, flanked by a 10-minute denaturation and 5-minute elongation
step. Data were analyzed by the DDCt method.10
Lung Tumor Tissue Collection
Human lung tissue and corresponding clinical data were collected under
a tissue banking protocol approved by the University of Colorado Institu-
tional Review Board. Informed consent was obtained from each partici-
pant. The stage reported is the pathologic stage after surgical resection
according to American Joint Committee on Cancer guidelines. Tumor sam-
ples and normal-appearing tissue from resected lobes were collected in
RNALater (Qiagen). Complementary DNA and subsequent quantitative
RT-PCR were prepared as described above.
Statistical Analysis
All data distributions were inspected before statistical analysis. The Stu-
dent t test was performed for 2-group comparisons, and the analysis of var-
iance test was performed when comparing 3 or more groups. No multiple
comparison was conducted. StatView version 5.0 was used for all statistical
analysis (SAS Institute, Inc, Cary, NC).gery c December 2012
TABLE 1. Cell line characteristics
Cell line Tumor type EGFR K-ras p53 NF-kB with sPLA2 inhibition ERK 1/2 with sPLA2 inhibition sPLA2
SW1573 BAC WT Mut WT Strong decrease Strong increase More
H2009 Adenoca WT Mut Mut Decrease Strong increase More
H358 BAC WT Mut Mut Decrease Strong increase Less
A549 Adenoca WT Mut WT Strong decrease Decrease Less
Strong attenuation of NF-kB activity was correlated with WT p53. EGFR, Epidermal growth factor receptor; NF-kb, nuclear factor kappa-b; sPLA2, secretory phospholipase
A2; ERK, extracellular signal-regulated kinase; BAC, bronchoalveolar carcinoma; WT, wild-type; Mut, mutant; Adenoca, adenocarcinoma.
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sPLA2IIa Expressed in K-ras Mutant Lung Cancer
Cells
Group IIa sPLA2 expression varies in K-ras mutant lung
cancer cells. SW1573 and H2009 express more sPLA2IIa
messenger RNA (mRNA) compared with H358 and A549
cells (Figure 1, A). Protein analysis by Western blot and
immunofluorescence corroborate this finding (Figure 1, B
and C).Cell Survival in K-ras Mutant Lung Cancer Cells
Depends on sPLA2IIa Expression
sPLA2IIa inhibition led to concentration-dependent apo-
ptosis and cell death in all K-ras mutant lung cancer cells
(Figure 2). Cells with higher baseline sPLA2IIa wereFIGURE 1. K-ras mutant lung cancer cell lines analyzed for baseline group IIa
SW1573 and H2009 cells expressing more sPLA2IIa compared with H358 and A
transcription polymerase chain reaction (RT-PCR),mean SEM, *P<.05, n¼
ern blot. Graph of densitometry, mean  SEM, **P<.005, n ¼ 4 (B). Immun
duplicate, sPLA2IIa ¼ red, cell membrane ¼ green, nuclei ¼ blue (C). IgG, Im
The Journal of Thoracic and Carmore susceptible to cell death with sPLA2IIa inhibition.
Early apoptosis detected by annexin V staining after 8 hours
of sPLA2IIa inhibition was increased in SW1573 and
H2009 cells compared with H358 and A549 cells
(Figure 2, A). The MTT assay confirmed concentration-
dependent cell death after 24 hours of sPLA2IIa inhibition,
again with increased vulnerability in cells with higher
sPLA2IIa expression (Figure 2, B).sPLA2IIa Inhibition in K-ras Mutants Decreases
NF-kB Phosphorylation
Previous work has demonstrated that sPLA2IIa inhibi-
tion–associated apoptosis is related predominantly to de-
creased NF-kB activity.4 We confirmed that NF-kB
phosphorylation is decreased with sPLA2IIa inhibition insecretory phospholipase A2 (sPLA2IIa) expression. Expression varies with
549 cells. Messenger RNA (mRNA) was evaluated by quantitative reverse-
5, run in triplicate (A). sPLA2IIa protein expression was evaluated byWest-
ofluorescence for sPLA2IIa was used for additional protein, n ¼ 3 run in
munoglobulin G; GAPDH, glyceraldehyde 3-phosphate dehydrogenase.
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FIGURE 2. Group IIa secretory phospholipase A2 (sPLA2IIa) expression inhibition promotes concentration-dependent apoptosis and cell death in lung
cancer cell lines, and cytotoxicity of sPLA2IIa inhibition parallels the level of sPLA2IIa expression. SW1573 and H2009 cells experience more apoptosis
at 20 and 40 mmol/L compared with H358 and A549 cells. Percent of cells with annexin V staining were normalized to staining of the respective vehicle
control, mean SEM, *P<.03 compared with SW1573, H2009. **P<.01 compared with vehicle control, n ¼ 3-4 (A). The 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) assay was used to assay cell viability after sPLA2IIa inhibition. LD50 at 24 hours increases as sPLA2IIa expression
decreases, mean  SEM, *P<.003, n ¼ 3 run in triplicate (B).
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Sall K-ras mutant cells, whereas ERK 1/2 phosphorylation
increases in 3 cell lines but decreases in A549 cells
(Figure 3). H2009 and H358 cells have a more modest de-
crease in NF-kB compared with SW1573 and A549 cells.
H2009 and H358 cells are both p53 mutant.
Human Lung Tumors Express sPLA2IIa
Fifteen lung tumors were examined for sPLA2IIa mRNA
expression. One metastatic colon adenocarcinoma and 1 in-
vasive esophageal adenocarcinoma were included in analy-
sis for comparison. Lung tumors express detectable levels of
sPLA2IIa mRNA (Figure 4). Although squamous and K-ras
mutant tumors are less common in our cohort, there is a trend
toward increased expression of sPLA2IIa in squamous tu-
mors. In K-ras mutant tumors there is evidence of increased
sPLA2IIa expression with increasing stage. Both large cell
neuroendocrine tumors express low levels of sPLA2IIa.
DISCUSSION
This is the first study to specifically explore the role of
sPLA2IIa in K-ras mutant lung cancer. Consistent with1482 The Journal of Thoracic and Cardiovascular Surour hypothesis, sPLA2IIa is a cytotoxic target in K-ras
mutant lung cancer cells. Our finding that in vitro sensi-
tivity to sPLA2IIa inhibition correlates with baseline
sPLA2IIa expression, regardless of p53 mutation status,
suggests that sPLA2IIa expression may predict response
to sPLA2IIa inhibition. Analysis of sPLA2IIa expression
in human lung tumors revealed some trends that we did
not anticipate. Expression increases with cancer stage in
K-ras mutant tumors, but it does not necessarily increase
with stage of non–small cell lung cancers overall. In ad-
dition, we found a trend of relatively high expression in
squamous cell tumors, another subset of lung tumors
that presently lacks targeted therapy. These findings are
intriguing. Not only do they suggest that sPLA2IIa may
be a more sensitive biomarker for a subset of tumors,
but small molecule inhibitors to sPLA2IIa have already
been trialed for inflammatory disease,11 thus underscor-
ing the possibility for rapid translational study in lung
cancer.
Although sPLA2 inhibition significantly attenuated
NF-kB activity in all lung cancer cell lines tested, cellsgery c December 2012
FIGURE 3. Group IIa secretory phospholipase A2 (sPLA2IIa) inhibition attenuates nuclear factor kappa-b (NF-kB) activity in all cell lines, with a variable
effect on extracellular signal-regulated kinase (ERK) 1/2 activity. NF-kB attenuation does not correlate with sPLA2IIa expression level. Both H2009 and
H358 (white bar graphs) are mutant p53 and demonstrate a more modest decrease in NF-kB activity (vc, vehicle control). Representative Western blots
with corresponding densitometry, mean  SEM, *P<.05, **P<.01, #P<.001, n ¼ 3-5.
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Swith mutant p53 had a less robust decrease in NF-kB activ-
ity. Other investigators have demonstrated a relationship be-
tween mutant p53 and increased baseline NF-kB
activity.12,13 Our data corroborate this observation and
further advance our understanding of the relationship
between sPLA2IIa and NF- kB by demonstrating that
sPLA2IIa inhibition has a more modest effect on the
activity of NF-kB in cancer cells where baseline activity
is high. Additional studies are needed to determine
whether this observation has implications for the effect of
sPLA2IIa inhibition on downstream NF-kB targets such as
metastasis-associated adhesion molecules and expression
of inducible growth factors.5,14-17The Journal of Thoracic and CarAn interesting and unexpected finding from our tumor
analysis was that sPLA2IIa expression was increased in
squamous tumors. Kupert and associates3 recently pub-
lished strong sPLA2IIa protein staining in non–small cell
lung tumor cores compared with normal lung tissue, includ-
ing 100% of squamous cell tumor cores, although they did
not quantify differences between histologic subtypes.3 This
trend requires focused investigation of more squamous tu-
mors inasmuch as there are currently no targeted therapies
for this subset of non–small cell lung cancers. Furthermore,
there is potential to examine the relationship between spe-
cific genetic alterations in squamous tumors and the tumor
promoting activity of sPLA2IIa.
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FIGURE 4. Human lung tumors express group IIa secretory phospholipase A2 (sPLA2IIa). Primary lung tumors (n ¼ 15), invasive esophageal adenocar-
cinoma (n ¼ 1), lung metastasis from colon adenocarcinoma primary (n ¼ 1). K-ras mutant adenocarcinomas (gray) express increasing levels of sPLA2IIa
with increasing stage. Squamous cell carcinomas (black) express higher levels of sPLA2IIa. Samples that did not include K-ras, ALK, or epidermal growth
factor receptor (EGFR) mutant status indicate patients that did not consent to mutation analysis. Messenger RNA evaluated by quantitative reverse-
transcription polymerase chain reaction (RT-PCR), samples run in triplicate. LCNEC, Large cell neuroendocrine carcinoma; mut, mutant; wt, wild-type;
s/p, status post; XRT, radiation therapy.
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related tumor growth are predominantly inflammatory,
including NF-kB and the arachidonic acid–eicosanoid path-
way.14,19,20 Mechanistic investigation of how sPLA2IIa
effects production of tumor-promoting eicosanoids, including
its interactions with other phospholipase enzymes, is ongoing.
In addition, sPLA2IIa is a secretedmoleculewith potential au-
tocrine and paracrine signaling capability.21 Ongoing studies
aim to clarify the effect of sPLA2IIa inhibition on sPLA2IIa
production and secretion with implications for understanding1484 The Journal of Thoracic and Cardiovascular Surthe role of sPLA2IIa in the tumor microenvironment to
promote tumor progression and metastasis.
A limitation of this study is the use of a single small mol-
ecule inhibitor. We have previously presented comparable
results with RNA interference of sPLA2IIa, resulting in de-
creased tumor growth in an animal model.4 In addition, our
tumor tissue analysis was limited owing to small sample
size. Furthermore, we were only able to analyze mRNA
secondary to the limited amount of tissue available to us.
The analysis of RNA and protein in the lung cancer cellgery c December 2012
Yu et al Evolving Technology/Basic Sciencelines mostly demonstrates a parallel relationship between
sPLA2 IIa mRNA transcript and sPLA2IIa protein expres-
sion. Future studies will need to include an analysis of pro-
tein expression of sPLA2IIa in tumors.
In summary, we have outlined the potential of sPLA2IIa
as a global target for lung cancer therapy—sPLA2 inhibition
is cytotoxic and potency correlates with baseline sPLA2 ex-
pression. Examination of human lung tumors suggests
sPLA2IIa has particular relevance for K-ras mutant and
squamous cell tumors, 2 lung cancer subsets that presently
pose therapeutic challenges. These data contribute to grow-
ing evidence of a role for sPLA2IIa in lung cancer that de-
serves further translational investigation.References
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